Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$194k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
6.8% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
8
users have followed this narrative
New
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
2.0% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
12
users have liked this narrative
2
users have commented on this narrative
19
users have followed this narrative
8 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
2.9% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
15
users have liked this narrative
4
users have commented on this narrative
16
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
47.4% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
4DMedical
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Acquisitions, Philips Partnerships And FDA Approvals Will Expand Market Reach
Key Takeaways Strategic acquisitions, partnerships, and regulatory approvals are poised to enhance market presence, revenue, and net margins through expanded distribution and high-margin services. Geographic expansion and new technology development aim to increase market penetration, scan volumes, and capture significant market share, improving overall financial performance.
View narrative
AU$0.72
FV
28.3% undervalued
intrinsic discount
102.26%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
5 days ago
author updated this narrative
Rekor Systems
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
TxDOT Order And Federal Focus Will Expand AI Markets
Key Takeaways Accelerated adoption of Rekor's AI-powered solutions by government agencies and national infrastructure initiatives is fueling growth and expanding long-term market opportunities. Shift toward SaaS and Data-as-a-Service models is improving revenue predictability, supporting margin expansion, and positioning the company closer to sustaining profitability.
View narrative
US$4.00
FV
73.8% undervalued
intrinsic discount
18.59%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
31
users have followed this narrative
5 days ago
author updated this narrative
PowerCell Sweden
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Growing OEM Partnerships And Decarbonization Will Unlock New Opportunities
Key Takeaways The company's strong OEM partnerships, technology commercialization, and regulatory support are driving revenue growth, diversification, and smoother earnings across expanding markets. Operational efficiency, disciplined cost control, and expanding royalty streams enhance profitability and reduce exposure to product sales volatility.
View narrative
SEK 40.00
FV
27.2% undervalued
intrinsic discount
18.15%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
12
users have followed this narrative
5 days ago
author updated this narrative
Sedana Medical
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
US Entry And European Sales Will Expand Market Opportunity
Key Takeaways U.S. market entry and expanding pediatric indications are set to significantly accelerate revenue and long-term growth opportunities. Clinical advantages and operational improvements strengthen market position, support pricing power, and drive sustainable margin expansion.
View narrative
SEK 21.00
FV
23.8% undervalued
intrinsic discount
23.31%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
5 days ago
author updated this narrative
Innate Pharma
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities
Key Takeaways A robust pipeline of innovative oncology therapeutics and drug candidates highlights strong R&D productivity potentially leading to substantial future earnings. Strategic partnerships, breakthrough therapy designations, and clinical trial progression indicate potential accelerated market entry and revenue growth in oncology treatments.
View narrative
€4.35
FV
53.6% undervalued
intrinsic discount
44.23%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
5 days ago
author updated this narrative
Quantum
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Subscription Model And DXi Sales Will Drive Future Success
Key Takeaways Quantum's shift to a subscription model boosts recurring revenue, enhancing profitability and cash flow stability amid growing ARR. Strategic equity and cost improvements reduce debt and enhance margins, while product and international deal growth bolster future earnings.
View narrative
US$19.00
FV
64.1% undervalued
intrinsic discount
1.59%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
5 days ago
author updated this narrative
Modiv Industrial
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Recycling Legacy Assets And Reshoring Trends Will Drive Industrial Transformation
Key Takeaways Strategic asset recycling and industry trends are expected to enhance earnings growth, revenue stability, and long-term cash flow visibility. Conservative leverage and rising institutional demand position the company for improved margins and potential valuation premium over time.
View narrative
US$17.50
FV
15.7% undervalued
intrinsic discount
1.19%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
5 days ago
author updated this narrative
Coherus Oncology
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Upcoming Clinical Data Will Reshape Immuno-Oncology Amid Uncertainties
Key Takeaways Advancement of clinical pipeline and increased physician adoption are expected to drive strong revenue growth and strengthen market position in high-need oncology indications. Strategic global partnerships and operational efficiency initiatives support improved profitability, lower financial risk, and long-term sustainable earnings expansion.
View narrative
US$4.70
FV
77.2% undervalued
intrinsic discount
-21.89%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
5 days ago
author updated this narrative
Hexagon Purus
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
European Incentives And Cost Cuts Will Advance Hydrogen Mobility
Key Takeaways Government incentives and expanding partnerships are boosting demand and positioning Hexagon Purus for recurring revenue and margin improvements in zero-emission mobility markets. Cost reduction initiatives and a diversified order backlog enhance profitability, reduce risk, and provide strong forward revenue visibility amidst decarbonization trends.
View narrative
NOK 3.37
FV
45.8% undervalued
intrinsic discount
35.55%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
5 days ago
author updated this narrative
Value any company in seconds
Popular companies